A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
David McMullin,1 David Clark,1 Bill Cavanagh,1 Paul Karpecki,2 Todd C Brady1 1Aldeyra Therapeutics, Inc, Lexington, MA, USA; 2Kentucky Eye Institute, Lexington, KY, USACorrespondence: Todd C BradyAldeyra Therapeutics, Inc, 131 Hartwell Avenue, Suite 320, Lexington, MA, 02421, USATel +1 781 761-4904E...
Saved in:
| Main Authors: | McMullin D, Clark D, Cavanagh B, Karpecki P, Brady TC |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/8ed6c8cfce4d4c78970537ad6781fa01 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
by: Nichols KK, et al.
Published: (2018) -
Dry eye syndrome: developments and lifitegrast in perspective
by: Lollett IV, et al.
Published: (2018) -
The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
by: Hovanesian J, et al.
Published: (2020) -
Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
by: Pepose JS, et al.
Published: (2019) -
Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
by: Gonzalez AL
Published: (2018)